pregnancy management	
evaluations can include:	
evaluations include:	
mothertobaby	
evaluations can include the following:	
use of antiepileptic medication during pregnancy reduces this risk	
search clinicaltrials	
see mothertobaby for further information on medication use during pregnancy	
org	C19711//Professional Organization or Group//NCI
therapies under investigation	
other	G-A609//Other//SNMI	2.16.840.1.113883.1.11.10616//Other//HL7V3.0	NHIS//Adult//NCI	CES-D//Other//NCI	C17649//Other//NCI_NICHD	TCGA//Enterovirus//NCI	LA46-8//Other//LNC	74964007//Other//SNOMEDCT_US	U003446//Other//MTH	U000265//OTHER//CCPSS	SDTM-NSYSPCID//OTHER//NCI_CDISC	SDTM-ACSPCAT//OTHER//NCI_CDISC	SDTM-INTTYPE//OTHER//NCI_CDISC	SDTM-NCOMPLT//OTHER//NCI_CDISC	SDTM-SDTHSDTP//OTHER//NCI_CDISC	U000081//Other//AIR	C53289//Other Health Care Professional//NCI	C38290//OTHER//NCI_FDA	135//OTHER//NCI_FDA	O//In Process//HL7V2.5	ORH//Other//HL7V2.5	OT//Occupational Therapy//HL7V2.5	5//Conservator//HL7V2.5	99//Other//HL7V2.5	4//2nd Operative//HL7V2.5	OTH//Other manufacturer//HL7V2.5	MTHU000080//Other//OMIM	LP21049-9//Other//LNC	MTHU029809//Other//LNC	52483-5//Other:-:Pt:^Patient:-//LNC	349//Other//SOP	C118472//Other//NCI_FDA	C123269//OTHER//NCI_FDA
males	U002790//Males//LCH	D008297//Male//MSH	NOCODE//Developmental arithmetic disorder//MTH	0000007693//male//CHV	0000015961//male//CHV
females	U001749//Females//LCH	D005260//Female//MSH	NOCODE//Developmental arithmetic disorder//MTH	0000004948//female//CHV	0000015888//female//CHV
molecular genetic testing	
identification of at-risk relatives	
early determination of the genetic status of males at risk	
determination of genetic status of females at risk	
obstetric issues	
newborn males	
cys282tyr	
particularly important are:	
240 (170)	
a parent, sib, or child	
first-degree relatives share about half of their genes	
a first cousin, great-grandparent, or great-grandchild	
during pregnancy	
see www	
monitoring for these possible complications is recommended	
the characteristic urinary steroid profile:	
significantly elevated metabolites associated with:	
fertility may be a concern	
no reports describe reproduction in individuals with pord	
hepatic drug metabolism	
the common pathogenic variant p	
stress should be minimized by providing good analgesia	
urinalysis	A35002//urinalysis//ICPC2P	D016482//Urinalysis//MSH	P-4150//Urinalysis//SNM	LP32744-2//Urinalysis//LNC	MTHU000144//Urinalysis//LNC	1011229//Urinalysis//CPT	10046509//Urinalysis//MDR	6355//Urinalysis//MEDLINEPLUS	27171005//Urinalysis//SNOMEDCT_US	55020//Urinalysis//PSY	C17241//Urinalysis//NCI	DEI//Urinalysis//ALT	NOCODE//Developmental arithmetic disorder//MTH	0012139//URINALYSIS//CCPSS	0000007220//urinalysis//AOD	0633-5828//urinalysis//CSP	U000062//urinalysis//MTH	0000012779//urinalysis//CHV	CDR0000046641//urinalysis//NCI_NCI-GLOSS	12488//urinalysis//MEDCIN
a single urinalysis is sufficient in a male	
relatives who have the family-specific pathogenic variant should:	
undergo alps-specific evaluations at initial diagnosis (e	
, lymphoma) become apparent (see surveillance)	
severe dyslipidemia	
and hyperglycemia	
intensive multidisciplinary surveillance of any pregnancy would be mandatory	
leu167del variant	
if the apoe p	
a woman with the apoe p	
they are usually identified during family screening	
plasma quantitative amino acid analysis	
analysis of enzymatic activity in red blood cells	
all pregnancies had a good outcome	
peripartum intensive monitoring is advised	
medication-associated risks to the fetus	
, a beta-blocker) prior to conception	
ecg, with consideration of signal-averaged electrocardiogram	
echocardiogram	10014113//echocardiogram//MDRDUT	X77c1//Echocardiography//RCD	40701008//Echocardiography//SNOMEDCT_US	0000426//ECHOCARDIOGRAM//CCPSS	0000004246//heart ultrasound//CHV	14540//echocardiogram//MEDCIN	C37945//Echocardiogram//NCI_FDA
holter monitoring	10020357//holter monitoring//MDRDUT	0000004328//holter monitor//CHV	C38064//Holter Monitoring//NCI	D015716//Electrocardiography, Ambulatory//MSH
cardiac mri	X70oi//Cardiac MRI//RCD	75565//Cardiac magnetic resonance imaging for velocity flow mapping (List separately in addition to code for primary procedure)//CPT	75557//Cardiac magnetic resonance imaging for morphology and function without contrast material//CPT	75561//Cardiac magnetic resonance imaging for morphology and function without contrast material(s), followed by contrast material(s) and further sequences//CPT	10076378//Cardiac MRI//MDR	241620005//Cardiac MRI//SNOMEDCT_US	0000032923//cardiac MRI//CHV	29381//magnetic resonance imaging of heart//MEDCIN
however, prenatal physiotherapy may be indicated	
affected women should continue biotin and thiamine therapy during pregnancy	
an optimal prenatal dose has not been determined	
pregnancy may increase the risk of diabetic decompensation	
for an affected mother	
no pregnancy manaagement issues are known	
for an affected child	
no special management is required during pregnancy	
pregnant females with classic 21-ohd cah	
polyhydramnios	O40//Polyhydramnios//ICD10	10036079//Polyhydramnios//MDR	D006831//Polyhydramnios//MSH	L270.//Polyhydramnios//RCD	M-29450//Polyhydramnios//SNM	D8-22100//Polyhydramnios//SNMI	657.0//Polyhydramnios//ICD9CM	N0000001561//Polyhydramnios [Disease/Finding]//NDFRT	C92848//Polyhydramnios//NCI	MTHU036439//Polyhydramnios//OMIM	HP:0001561//Polyhydramnios//HPO	86203003//Polyhydramnios//SNOMEDCT_US	657//Polyhydramnios//ICD9CM	NOCODE//Developmental arithmetic disorder//MTH	0042417//POLYHYDRAMNIOS//CCPSS	0000006333//polyhydramnios//CHV	MTHU060945//polyhydramnios//ICPC2ICD10ENG	34306//polyhydramnios//MEDCIN	10020486//Polyhydramnios//MDRFRE
the cause of polyhydramnios is unknown	
macrosomia	10025394//Macrosomia//MDR	D8-70310//Exceptionally large baby//SNMI	MTHU032584//Macrosomia//OMIM	C119954//Macrosomia//NCI_NICHD	38206000//Exceptionally large at birth//SNOMEDCT_US	0000023656//macrosomia//CHV	10053718//Macrosomia//MDRITA	HP:0001520//Large for gestational age//HPO
molecular genetic testing for the causative contiguous gene deletion	
otologic examination and audiologic assessment	
0 mg im, folic acid 5	
of the 16 women, hemorrhage occured in ten	
6% compared with 1	
see malignant hyperthermia susceptibility for more details	
deterioration during pregnancy may precipitate preterm delivery	
mode of delivery is based on usual obstetric indications	
data regarding teratogenicity of itraconazole are limited	
the infants were normal	
early diagnosis of relatives (i	
completely asymptomatic individuals need not be tested	
no issues are known	
however, experience is limited	
females with ciss may conceive normally	
no complications during pregnancy have been reported to date	
the prescription of clonidine should not be discontinued abruptly	
data on pregnancies in cms are limited	
trpv4-associated neuromuscular disorders	
trpv4-associated skeletal dysplasias	
no specific pregnancy management recommendations have been published	
the symptoms of cmt can worsen during pregnancy	
in particular: cramps, subjective sensitivity (e	
, paresthesias), difficulty walking, and fatigue	
no obvious effect has been observed	
acute fatty liver of pregnancy	10000746//Acute fatty liver of pregnancy//MDR	X307E//Acute fatty liver of pregnancy//RCD	C537957//Acute fatty liver of pregnancy//MSH	716379000//Acute fatty liver of pregnancy//SNOMEDCT_US	NOCODE//Developmental arithmetic disorder//MTH	0000026433//acute fatty liver of pregnancy//CHV
maternal liver disease	
it is appropriate to evaluate relatives at risk (e	
treatment with chenodeoxycholic acid should not be interrupted during pregnancy	
otherwise serial ancs can be evaluated	
other findings included:	
dose adjustment may also be required post partum	
pregnancy management for heterozygous females	
, coronary artery disease)	
, left ventricular enlargement but normal function	
in most cases, pregnancy is contraindicated in dcm	
evaluations may include:	
consideration of other testing (e	
during pregnancy the maternal hemoglobin level must be monitored	
intrauterine growth retardation	X70Er//Fetal growth retardation//RCD	F-33710//Intrauterine growth retardation//SNM	MTHU001305//Intrauterine growth retardation//OMIM	HP:0001511//Intrauterine growth retardation//HPO	10022819//Intrauterine growth retardation//MDR	764.9//Intrauterine growth retardation//MTHICD9	22033007//Fetal growth restriction//SNOMEDCT_US	2403-8925//prenatal growth disorder//CSP	0000004992//iugr//CHV	35631//intrauterine growth retardation//MEDCIN	1013735//INTRAUTERINE GROWTH RETARDATION//CCPSS	N0000001235//Fetal Growth Retardation [Disease/Finding]//NDFRT	D005317//Fetal Growth Retardation//MSH
preeclampsia	NOCODE//Sepsis//COSTAR	D-2502//Preeclampsia//SNM	MTHU004758//Preeclampsia//OMIM	C85021//Preeclampsia//NCI	N0000002473//Pre-Eclampsia [Disease/Finding]//NDFRT	398254007//Pre-eclampsia//SNOMEDCT_US	1508//High Blood Pressure in Pregnancy//MEDLINEPLUS	sh91004039//Preeclampsia//LCH_NW	HP:0100602//Preeclampsia//HPO	D011225//Pre-Eclampsia//MSH	0054350//PREECLAMPSIA//CCPSS	U001572//PREECLAMPSIA//DXP	4001-0110//preeclampsia//CSP	0000010031//preeclampsia//CHV	10036485//Preeclampsia//MDRSPA
retroplacental hematoma	X40CH//Retroplacental hematoma//RCDAE	10054890//Retroplacental hematoma//MDR	10054798//Retroplacental haematoma//MDR	237293000//Retroplacental hematoma//SNOMEDCT_US	NOCODE//Developmental arithmetic disorder//MTH	0000036993//retroplacental hematoma//CHV	C117331//Retroplacental Thrombus//NCI_NICHD
in utero fetal death	
preterm delivery	O60//Preterm delivery//ICD10	MTHU008449//Preterm delivery//OMIM	HP:0001622//Premature birth//HPO	C92861//Preterm Birth//NCI_NICHD	0000021764//preterm delivery//AOD	0000016984//premature birth//CHV
telomere length testing	
they should be followed closely by a perinatologist	
recommendations vary by underlying genetic mechanism:	
two women reported mild deterioration of dystonia	
an increase in dose was required in one	
see mothertobaby	
org for further information on medication use during pregnancy	
2-q13	
caesarean section delivery may be required	
labor and delivery may progress very rapidly	
there is no clear advantage to vaginal vs	
cesarean delivery	59514//Cesarean delivery only//CPT	C46088//Cesarean Birth//NCI_NICHD	0000002703//caesarean section (C-section) delivery//CHV	200144004//Deliveries by cesarean//SNOMEDCT_US	34297//cesarean delivery//MEDCIN
delivery should be performed in a medical center	
pregnancy is not complicated by epp	
there is no information on pregnancy management in xlp	
measure α-gal a enzyme activity	
however, the indications for family testing are unresolved	
recommended genetic testing for at-risk family members	
pregnancy/fertility/hormone use	
visceral pain related to contractions during labor is perceived normally	
therefor, analgesia should be provided	
this is especially important when the p	
poncz & cohen 1996	
min et al 2008	
goldman, personal communication to author]	
diagnostic evaluations can include:	
molecular genetic testing for the familial gata1 pathogenic variant	
effect of anticonvulsants on hormonal methods of birth control	
effects of anticonvulsants on conception	
effect of pregnancy on anticonvulsant metabolism	
effect of pregnancy on maternal seizure control	
renal anomalies	MTHU010000//Renal anomalies//OMIM	HP:0000077//Abnormality of the kidney//HPO
skeletal differences such as club foot and craniosynostosis	
and umbilical and inguinal hernia	
baseline ultrasound of liver and kidneys prior to pregnancy	
consideration of referral to high-risk obstetrician	
metabolic control should be followed closely throughout the pregnancy	
abdominal ultrasound should be performed every six to 12 weeks	
the effect of pregnancy on inducing acute attacks is unpredictable	
in general, serious problems during pregnancy are unusual	
if the female is symptomatic (i	
range: 15%-50%)	
the following strategy is appropriate:	
perform iron studies (i	
no guidelines exist	
common practice is to withhold phlebotomy during pregnancy	
coli sepsis and pulmonary edema	
testing of populations at risk	
cessation of prophylactic antimicrobials is often advised during pregnancy	
ideally cancer screening exams would be planned around a pregnancy	
hyperpyrexia and its potential complications, including febrile seizures	
, first 28 days of life)	
no monitoring is needed for:	
8%) and preeclampsia (7	
7%)	
children because of their increased risk for anemia	
measurement of ldl-c level	
table 4	
degree of relatedness to an affected individual	
first degree 1	
second degree 2	
third degree 3	
cholesterol levels	0000019961//cholesterol level test//CHV	0000033881//cholesterol level test result//CHV
total cholesterol (ldl cholesterol) in mg/dl	
age	X7686//Age//RCD	424144002//Current chronological age//SNOMEDCT_US	LP28815-6//Age//LNC	MTHU010047//Age//LNC	C25150//Age//NCI_CDISC	TCGA//Enterovirus//NCI	SEND-STSPRM//Age//NCI_CDISC	NHIS//Adult//NCI	328408//Age//FMA	397669002//Age//SNOMEDCT_US	NOCODE//Developmental arithmetic disorder//MTH	0000000275//age//AOD	MTHU043134//age//ICPC2ICD10ENG	0000000813//age//CHV	0062735//AGE//CCPSS	CDISC-VARIABLE//AEOUT//NCI_CDISC	SEND-STSPRMCD//PPL//NCI_CDISC	D017127//produkty pokročilé glykace//MSHCZE	30525-0//Age:Time:Pt:^Patient:Qn//LNC
<20	
220 (155)	
230 (165)	
20-29	LA10396-2//20-29//LNC
250 (180)	
260 (185)	
30-39	LA10397-0//30-39//LNC
270 (190)	
280 (200)	
290 (210)	
40+	
290 (205)	
300 (215)	
310 (225)	
statins are contraindicated during pregnancy	
pharmacologic treatment	
statins are contraindicated in pregnancy due to concerns for teratogenicity	
nursing mothers should not take statins	
ldl apheresis is also occasionally used	
regarding other agents:	
pcsk9 inhibitors	N0000191730//PCSK9 Inhibitors [MoA]//NDFRT
use during pregnancy has not been well studied	
ezetimibe	341248//ezetimibe//RXNORM	EOR26LQQ24//ezetimibe//MTHSPL	256543//ezetimibe//MEDCIN	0000055188//ezetimibe//CHV	009817//ISOPROPYL ALCOHOL MISCELL SOLUTION, NON-ORAL//NDDF	C10AX09//ezetimibe//ATC	d04824//ezetimibe//MMSL	17026//ezetimibe//MMSL	NOCODE//Developmental arithmetic disorder//MTH	C47529//Ezetimibe//NCI	LP171397-5//Ezetimibe//LNC	N0000010117//Ezetimibe [Chemical/Ingredient]//NDFRT	DB00973//Ezetimibe//DRUGBANK	229065//Ezetimibe//MMSL	408041006//Ezetimibe//SNOMEDCT_US	409149001//Ezetimibe//SNOMEDCT_US	MTHU001012//Ezetimibe//USPMG	D000069438//Ezetimibe//MSH	N0000148785//EZETIMIBE//NDFRT	4021366//EZETIMIBE//VANDF
use during human pregnancy has not been well studied	
niacin	D009525//niacin//MSHCZE	U003226//Niacin//LCH	2275//methyldopa 50 mg/mL intravenous solution//MMSL	XM0l0//Nicotinic acid//RCD	bx8..//Nicotinic acid product//RCD	F-16330//Niacin//SNM	F-BB430//Niacin//SNMI	7393//Niacin//RXNORM	2679MF687A//Niacin//MTHSPL	N0000006449//Niacin [Chemical/Ingredient]//NDFRT	LP14887-1//Niacin//LNC	5376//B Vitamins//MEDLINEPLUS	MTHU002113//Niacin//LNC	sh85091698//Niacin//LCH_NW	C689//Niacin//NCI_CRCH	NSC0169454//Niacin//NCI_DTP	DB00627//Niacin//DRUGBANK	273943001//Niacin//SNOMEDCT_US	33970//Niacin//PSY	MTHU001014//Niacin//USPMG	NOCODE//Developmental arithmetic disorder//MTH	0000004764//niacin//AOD	3147-2013//niacin//CSP	d00314//niacin//MMSL	5169//LVP solution with potassium Invert Sugar 10% with Electrolytes (Travert with Electrolyte No.2) intravenous solution//MMSL	0000008699//niacin//CHV	001052//PHENYLPROPANOLAMINE HCL/PYRILAMINE MALEATE/PHENIRAMINE ORAL TABLET, EXTENDED RELEASE//NDDF	CDR0000556407//niacin//NCI_NCI-GLOSS	41282//vitamins niacin//MEDCIN	78886//antihyperlipemics niacin//MEDCIN	CDR0000038351//niacin//PDQ	N0000146039//NIACIN//NDFRT	4017661//NIACIN//VANDF	C74899//Vitamin B3//NCI_CDISC	SDTM-LBTEST//Glomerular Filtration Rate//NCI_CDISC
higher doses have been associated with toxicity	
risks during delivery include cephalopelvic disproportion	
pregnancy in women with parkinson disease is a rare event	
see hereditary hemorrhagic telangiectasia, pregnancy management	
see mothertobaby for more information on medication use during pregnancy	
edema may be exacerbated during pregnancy	
if the ptpn11, raf1,	
some carrier females develop gout in later years	
if the causal tgfbr1,	
pregnancy can be dangerous for women with lds	
it is appropriate to evaluate at-risk sibs during infancy	
measurement of plasma triglyceride concentration	
affected mother	
affected fetus	
0 cm	
at a root dimension <5	
0cm) before becoming pregnant	
pregnant women who have mcad deficiency must avoid catabolism	
for the purpose of early diagnosis and treatment	
for the purpose of kidney donation	
no pregnancy issues are particular to adtkd-umod	
thus, no particular recommendations can be made	
no prenatal or perinatal neurologic manifestations of mls are known	
using genomic testing that will detect the 15q13	
close monitoring for intrauterine growth retardation is warranted	
using genomic testing that will detect the 1q21	
3 microdeletion	
infertility may preclude pregnancy in some affected individuals	
men 2a	D018813//mnohočetná endokrinní neoplazie typ 2A//MSHCZE	N0000003862//Multiple Endocrine Neoplasia Type 2a [Disease/Finding]//NDFRT	C3226//Multiple Endocrine Neoplasia Type 2A//NCI
fmtc	155240//THYROID CARCINOMA, FAMILIAL MEDULLARY//OMIM
men 2b	D018814//mnohočetná endokrinní neoplazie typ 2B//MSHCZE	N0000003863//Multiple Endocrine Neoplasia Type 2b [Disease/Finding]//NDFRT	0000007922//men iii//CHV	C3227//Multiple Endocrine Neoplasia Type 2B//NCI
albumin-corrected calcium or ionized calcium for hyperparathyroidism	
, cardiac and renal defects)	
fetal monitoring should follow standard guidelines	
continuous epidural analgesia is highly recommended for labor and delivery	
therapies under investigations	
ultrasound abnormalities are not present in all affected pregnancies	
abnormal presentation of an affected fetus may complicate delivery	
no information on pregnancy management and outcomes is available	
penetrance rates, however, are not known	
the post-partum period is dangerous for the mother	
evaluation includes targeted molecular genetic testing for the fgfr3 c	
749c>g pathogenic variant	
evaluation for placenta previa	
otherwise, monitor renal findings (i	
additional testing is not indicated	
the first pregnancy ended in miscarriage at 19 weeks	
, pre-eclampsia)	
no treatment for the condition is available	
birth is usually normal and uncomplicated	
fetal akinesia often causes congenital contractures	
clonus persists after birth and is usually severe	
absence of respiratory movement necessitates mechanical support at birth	
if not, treatment can be withdrawn	
, avoidance of unattended swimming)	
see treatment of manifestations	
possible those who would benefit from initiation of treatment	
1994a, schwartz et al 1994b]	
it is recommended that every five years, asymptomatic	
standardized questionnaire to assess the presence of respiratory	
symptoms	Q000175//diagnosis//MSH	31//Medicines//MEDLINEPLUS	MTHU021540//Symptoms//LNC	sh85131555//Symptoms//LCH_NW	51140//Symptoms//PSY	NOCODE//Developmental arithmetic disorder//MTH	MTHU072482//symptoms//ICPC2ICD10ENG	2952//symptoms//MEDCIN	GENSYMPTOMS//SYMPTOMS//CST	780-789.99//SYMPTOMS//ICD9CM
family members are considered to have a positive screening	
evaluation (i	
, to possibly have pulmonary fibrosis) if they	
family members	19210//Family Members//PSY	D005190//Family//MSH	0000015886//family members//CHV
radiologic and histopathologic abnormalities suggestive of possible	
early interstitial lung disease	
it is unknown if these findings would	
become symptomatic fpf in the subjects	
see genetic	
genetic counseling purposes	
if the epor pathogenic variant in the family is known	
if no pathogenic variant has been identified in the family	
asymptomatic individuals:	
can be monitored periodically for renal function and urinary oxalate	
should maintain adequate hydration and avoid high-oxalate foods	
in addition:	
for those with the pathogenic variant p	
gly170arg or p	
phe152ile, pyridoxine should be supplemented	
, heterozygous for one hoga1 pathogenic variant)	
adequate fluid intake should be maintained throughout the pregnancy	
measurement of serum potassium concentration and blood pressure	
early diagnosis and treatment	
surveillance as outlined in surveillance	
see related genetic counseling issues	
presymptomatic diagnosis:	
permits early detection and treatment of complications and associated disorders	
reassures those found to be unaffected	
the literature on pregnancy and pkd is limited	
women with pah deficiency	
preconception	C89341//Preconception//NCI
assessment of early osteopenia risk	
discontinuation of lnaa treatment	
post partum	0000016019//the period after childbirth//CHV	LP20597-8//post partum//LNC	NOCODE//ABDUCENS NERVE PALSY IN CHILDREN, BENIGN, RECURRENT//DXP	D049590//Periodo post partum//MSHITA
provide coordinated care in the post-partum period	
spasticity generally does not change significantly with pregnancy	
pregnancy is generally not complicated by f-pct	
newer effective therapies may decrease the risk	
and an audiology evaluation	
see published guidelines/consensus statements	
prophylactic anticoagulation during pregnancy:	
is recommended for all women:	
should be considered for:	
all women received a course of postpartum anticoagulation	
all asymptomatic homozygous women	
prevention of pregnancy loss	
trialregister	
nl, ntr 3361)	
studies suggesting that prophylactic anticoagulation improves pregnancy outcome:	
5% and 15	
other pregnancy complications	
young or uncooperative children may require examination under anesthesia	
recommended doses during pregnancy are 10 mg/kg/day	
evaluation can be accomplished by:	
pregnancy in affected women appears to be generally uncomplicated	
that has documented lqts	
in which evaluation for lqts has not been performed	
or both of the following:	
weight gain during pregnancy can further impair gait ataxia	
affected women may be on medications (e	
, antiepileptics) to control the symptoms of sca17	
successful pregnancies have occurred in women with short syndrome	
if present, diabetes mellitus is managed as appropriate	
the following are appropriate:	
clinical appraisal and lateral skull radiograph as indicated	
no pregnancy complications have been reported	
almost all develop thrombocytopenia during pregnancy	
it can be addressed on three levels:	
maternal	X78ym//Maternal//RCD	S-10120//Mother, NOS//SNMI	72705000//Mother//SNOMEDCT_US	0000008266//mother//CHV	D012578//Escolas Maternais//MSHPOR	MTHU004756//Maternal//OMIM	C89336//Maternal//NCI	LA26320-4//Maternal//LNC	NOCODE//Developmental arithmetic disorder//MTH	CDR0000446106//maternal//NCI_NCI-GLOSS	C71383//Maternal Relative//NCI
avoidance of emergency c-section for fetal distress	
fetal	C13235//Fetus//NCI	LA10429-1//Fetal//LNC	T-F5200//Fetus, NOS//SNMI	NOCODE//Developmental arithmetic disorder//MTH	2401-7877//embryo/fetus//CSP	0052851//FETAL//CCPSS
familial	CDR0000460148//familial//NCI_NCI-GLOSS	C25173//Family//NCI	X78yg//Familial//RCD	255401001//Familial//SNOMEDCT_US	NOCODE//Developmental arithmetic disorder//MTH	0000024682//familial//CHV
org for more information on medication exposure during pregnancy	
audiology	U000427//Audiology//LCH	D001298//Audiology//MSH	C61153//Audiology//NCI	LP135586-8//Audiology//LNC	sh85009470//Audiology//LCH_NW	04540//Audiology//PSY	NOCODE//Developmental arithmetic disorder//MTH	0000001584//audiology//CHV	AU//Audio data (HL7 V2.3 and later)//HL7V2.5
abr, dpoae	
such test results need to be interpreted with caution	
, vhl syndrome or other hereditary disorder)	
during pregnancy, affected women may develop small new lesions	
penetrance is complete (i	
delayed, secondary postpartum bleeding may be a problem	
wolfram syndrome	D014929//Wolfram Syndrome//MSH	N0000003167//Wolfram Syndrome [Disease/Finding]//NDFRT	C35133//Wolfram Syndrome//NCI_NICHD	NOCODE//Developmental arithmetic disorder//MTH	0977-5687//hearing disorder//CSP	2042-6601//optic nerve disorder//CSP	660//Wolfram syndrome//JABL	X008t//Diabetes insipidus,diabetes mellitus, optic atrophy and deafness//RCD	10078338//Wolfram syndrome//MDR	70694009//Diabetes mellitus AND insipidus with optic atrophy AND deafness//SNOMEDCT_US	0000013178//wolfram syndrome//CHV
low-frequency sensorineural hearing loss (lfsnhl)	
pregnancies in women with ws are high risk	
zinc has been used effectively during pregnancy	
org for more information on medication use during pregnancy	
there are no other special recommendations for pregnancy management	
regular monitoring with pregnancy tests is indicated	
